Rapid Diagnostics Market Report 2026

Rapid Diagnostics Market Overview

• Rapid Diagnostics market size has reached to $36.08 billion in 2025 • Expected to grow to $64.79 billion in 2030 at a compound annual growth rate (CAGR) of 12.4% • Growth Driver: Surge In Infectious Disease Fueling The Growth Of The Market Due To Rising Transmission And Need For Timely Detection • Market Trend: Advancements In Rapid Testing Enhance Accuracy And Speed In Healthcare • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rapid Diagnostics Market?

Rapid diagnostics refer to medical tests designed to quickly detect the presence or absence of specific pathogens, conditions or biomarkers, typically delivering results within minutes to a few hours. These tests are commonly used at the point of care, enabling timely clinical decisions, early treatment, and improved patient outcomes. The main product type of rapid diagnostics include kits, reagents, instruments and other product types. Kits Pre-assembled diagnostic tools that include all essential components such as reagents, assay devices, and instructions for performing specific tests quickly and accurately. The various platforms include immunoassays, molecular detection and other rapid diagnostic platforms, for various applications such as blood glucose testing, infectious disease testing, cardio metabolic testing, pregnancy and fertility testing, fecal occult blood testing, coagulation testing and toxicology testing. The rapid diagnostics is distributed through channels such as hospital pharmacies, brick and mortar, e-commerce and other distribution channels. The key end uses include diagnostic centers, homecare settings, hospital pharmacies and other end users.

What Is The Rapid Diagnostics Market Growth Forecast?

The rapid diagnostics market size is expected to see rapid growth in the next few years. It will grow to $64.79 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing investments in molecular diagnostics, rising adoption of connected diagnostic devices, expansion of home-based testing solutions, growing focus on personalized diagnostics, increasing use of data-driven clinical workflows. Major trends in the forecast period include increasing use of point-of-care diagnostic platforms, rising adoption of molecular rapid testing, growing integration of digital result interpretation, expansion of portable diagnostic instruments, enhanced focus on early clinical decision support.

Global Rapid Diagnostics Market Segmentation

1) By Product Type: Kits, Reagents, Instruments, Other Product Types 2) By Platform: Immunoassays, Molecular Detection, Other Rapid Diagnostic Platforms 3) By Application: Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy and Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing 4) By Distribution Channel: Hospital Pharmacies, Brick and Mortar, E-Commerce, Other Distribution Channels 5) By End Use: Diagnostic Centers, Homecare Settings, Hospital Pharmacies, Other End Users Subsegments: 1) By Kits: Lateral Flow Assay Kits, PCR Kits, Immunoassay Kits, Microfluidic Kits, Molecular Diagnostic Kits, Multiplex Kits 2) By Reagents: Enzymes, Buffers, Probes and Primers, Stains and Dyes, Antibodies, Calibration and Control Reagents 3) By Instruments: PCR Machines, Lateral Flow Readers, Immunoassay Analyzers, Microfluidic Analyzers, Automated Sample Processors, Biosensors 4) By Other Product Types: Software and Data Management Tools, Sample Collection Devices, Accessories and Consumables, Calibration Standards, Point-of-Care Devices

What Is The Driver Of The Rapid Diagnostics Market?

The increasing prevalence of infectious disease is expected to propel the growth of the rapid diagnostics market going forward. Infectious disease refers to illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can be spread directly or indirectly from one person to another. The rise in prevalence of infectious diseases is driven by increased global travel, which contribute to faster transmission and higher infection rates. Rapid diagnostics help infectious diseases by enabling quick and accurate identification of pathogens, allowing for timely treatment decisions, reduced transmission, and improved patient outcomes. For instance, in May 2025, according to the The World Health Organization (WHO), Switzerland-based specialized agency of the United Nations responsible for international public health, since mid-February 2025, global SARS-CoV-2 (the virus responsible for causing COVID-19, an infectious disease)activity has been on the rise, based on data from sentinel sites, with the test positivity rate reaching 11%, a level last observed in July 2024. Therefore, the increasing prevalence of infectious disease are driving the rapid diagnostics industry.

Key Players In The Global Rapid Diagnostics Market

Major companies operating in the rapid diagnostics market are Johnson And Johnson Services Inc, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Hologic Inc, bioMerieux SA, QuidelOrtho Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Cepheid Inc, OraSure Technologies Inc, Nova Biomedical Corporation, Fujirebio Holdings Inc, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Abingdon Health plc, Abionic SA, LumiraDx Ltd

Global Rapid Diagnostics Market Trends and Insights

Major companies operating in the rapid diagnostics market are focusing on advancements and innovation, such as rapid diagnostic testing tools, to enhance diagnostic accuracy, reduce turnaround times, and improve patient outcomes in point-of-care settings. Rapid diagnostic testing tools refer to medical devices that quickly detect the presence of specific diseases or conditions, typically providing results within minutes at the point of care. For instance, in May 2025, SEKISUI Diagnostics a US-based medical diagnostics manufacturer, launched the OSOM RSV Test, a rapid diagnostic tool for detecting respiratory syncytial virus (RSV). This test is intended for use in professional healthcare settings and delivers results in just 15 minutes. It employs a rapid immunochromatographic assay to qualitatively detect RSV nucleoprotein antigen. The test uses anterior nasal swab specimens collected from patients showing symptoms of respiratory infection. Its quick turnaround time supports timely and effective clinical decision-making.

What Are Latest Mergers And Acquisitions In The Rapid Diagnostics Market?

In June 2023, Avacta Group a UK-based biotechnology company, acquired Coris Bioconcept SRL for an undisclosed amount. Through this acquisition of Coris BioConcept SRL, Avacta Group aims to expand its diagnostics portfolio and enhance its capabilities in rapid testing technologies for infectious diseases and antimicrobial resistance. Coris BioConcept SRL is a Belgium-based biotechnology company developing, manufacturing and marketing rapid diagnostic tests.

Regional Outlook

North America was the largest region in the rapid diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rapid Diagnostics Market?

The rapid diagnostics market includes revenues earned by providing services such as quick and accurate testing for diseases, infections, and medical conditions using point-of-care diagnostic tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The rapid diagnostics market consists of sales of quick diagnostic test kits and devices used for the rapid detection of diseases and medical conditions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rapid Diagnostics Market Report 2026?

The rapid diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rapid diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.